Compare Sirius XM Holdings Inc (SIRI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Sirius XM Holdings Inc trades at $30.24 (market cap $10.30B), while State Street SPDR S&P Biotech ETF trades at $154.38. The key difference: Sirius XM Holdings Inc pays a 3.53% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| SIRI | XBI | |
|---|---|---|
Market Cap | $10.30B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $31.22 | $164.28 |
52-Week Low | $19.92 | $85.16 |
Enterprise Value | $19.97B | — |
Dividend Yield | 3.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM (SIRI) trades at $30.29, down 0.98% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 12.97, net income margin of 9.86%, and a recent dividend payment. Revenue stabilized around $8.6B in 2025 after a dip in 2024, while debt-to-asset ratio improved to 35.63%.
Outlook is positive with analyst consensus at Buy (58% of ratings) and a $30.71 price target, though risks include competitive pressures and reliance on subscription growth. The YouTube ad partnership and inclusion in the S&P MidCap 400 provide catalysts, but investors should monitor Q2 2026 earnings due July 30 for confirmation of trends.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
